

ANSWERING REVIEWERS

Name of journal: *World Journal of Clinical Oncology*

Manuscript NO: 58857

Title: Chronic Myeloid Leukemia - From the Philadelphia chromosome to specific target drugs - a literature review

Reviewer's code: 00503536

Position: Peer Reviewer

Dear reviewer,

Thank you for the great evaluation and valuable comments on our manuscript. The suggestions you provided were crucial for the improvement of the quality of our manuscript. Aiming to attend to your suggestions, we listed the changes suggested by you below and they were highlighted in **yellow** at the manuscript file:

- 1) In the section of DIAGNOSIS we summarize the baseline diagnosis work-out according to the latest ELN guideline (Hochhaus et al. 2020);
- 2) We include the atypical CML management ;
- 3) The physiopathology, diagnosis and treatment of the blast crisis were summarized;
- 4) We discuss the immunotherapy directed to PD-1/PD-L1 signaling.

Best regards,

Fabício Freire de Melo

Reviewer's code: 05445979

Position: Peer Reviewer

Dear reviewer,

We are glad for the great evaluation and for your comments about our manuscript. Your suggestions were very useful in the improvement of the scientific quality of this article. Aiming to attend to your suggestions, the following changes were made:

- 1) All typographical errors listed by you have been rectified (highlighted in **blue** at the manuscript file);
- 2) The old ELN recommendations have been replaced by the latest (Hochhaus et al. 2020) (highlighted in **pink** at the manuscript file);
- 3) The example of resistance to TKIs could be misleading and has been replaced (highlighted in **pink** at the manuscript file);
- 4) The role of fish in cytogenetic control was emphasized (highlighted in **green** at the manuscript file);
- 5) The thrombocytopenia associated with dasatinib use were cited. (highlighted in **orange** at the manuscript file);
- 6) The OCT1 and ABCG2 resistance mechanisms were replaced. (highlighted in **blue** at the manuscript file);
- 7) The ongoing recruiting studies combining asciminib with other TKI were cited. (highlighted in **purple** at the manuscript file);
- 8) The absence of Table 1 reported by you were not detectable in our manuscript file. It could have occurred due to a problem when you performed the download or when you opened the manuscript file in your text editor software.

Best regards,

Fabrcio Freire de Melo.

Reviewer's code:

Position: Science Editor

Dear reviewer,

Thank you for the evaluation of our manuscript. Aiming to improve the quality of our manuscript and attend to your requirement, all authors of the references were listed.

Best regards,

Fabício Freire de Melo.